Hematology CME Courses

Hematology CME Courses

Credits: 1.0 (AMA PRA Category 1)
Format: Online Streaming Video
Price: Free
Release Date: May 12, 2016
Expiration Date: May 12, 2018
Summary:

Acute lymphoblastic leukemia (ALL) is one of a group of malignancies caused by cytogenetic DNA mutations of developing hematopoietic stem cell precursors and mostly common to children with peak incidence at 2-5 years of age. Although approximately 80% of ALL cases present in children, they also occur in adults.  The symptoms of ALL are non-specific and similar to those of acute myelogenous leukemia (AML), which patients usually have 1-3 months of complaints.

By the end of the session the participant will be able to:

  • Summarize the most impactful findings presented at ASH 2015 relating to ALL and apply them to patient cases, taking into account any relevant barriers to care.
  • Additional objectives to be dictated by clinical content
Credits: 1 (AMA PRA Category 1)
Format: Interactive Online, Online Streaming Video, PDF
Price: Free
Release Date: November 02, 2017
Expiration Date: November 02, 2019
Summary:

Multiple myeloma (MM) is a hematologic malignancy of the lymphocytes. All cases are marked by monoclonal gammopathy, and while the true cause is unknown, associated factors are thought to include: radiation, genetics, viral infections, and the human immunodeficiency virus. Helping the clinician discern the role of each of the first-line and more novel therapies, including monoclonal antibodies and proteasome, deacetylase, and 3 serine/threonine protein kinase inhibitor therapies – among others – based on the most up-to-date research merits continuing education programming in MM.

By the end of the session the participant will be able to:

  • Recall updates in the staging, prognosis, and diagnosis of MM.
  • Distinguish between the most appropriate treatment approaches to MM and apply them to practice, taking into account the following: treatment modalities and the recent clinical trial evidence supporting them.
  • Distinguish between the most appropriate treatment approaches to MM and apply them to practice, taking into account the following: evidence-based treatment guidelines, algorithms, and expert opinion.
  • Summarize the risk-benefit profiles of current and emerging therapies for the treatment of MM.
Credits: 1 (AMA PRA Category 1)
Format: Online Streaming Video
Price: Free
Release Date: September 13, 2017
Expiration Date: March 13th, 2018
Summary:

TOPICS OF INTEREST:

  • Disease- and patient-factors influencing treatment choices at relapse
  • Mechanisms of drug resistance and clonal heterogeneity
  • Emerging agents: Immunodulatory derivatives, novel pathway targets, second-generation proteasome inhibitors, and monoclonal antibodies
  • Drawing on clinical trials of emerging therapies to benefit patients



Credits: 11.5 (AMA PRA Category 1)
Format: Online Streaming Video
Price: $695
Release Date: July 15, 2018
Expiration Date: July 15, 2021
Summary:

In addition to detailed coverage of hematopoietic neoplasms, the Masters of Pathology Series — Hematopathology program covers selected topics in hemostasis, thrombosis, and red blood cell pathology commonly encountered in pathology practices. Designed for both the practicing pathologist and the pathologist in training, this CME course will help you to better:

  • Use results of immunophenotypic, genetic, and molecular studies when diagnosing hematopoietic neoplasms
  • Interpret the diagnostic tests used to evaluate hemoglobinopathy, thalassemia, and selected hemostasis disorders
  • Understand practical aspects of new developments and updates as you prepare for exams or certification




Credits: 26 (AMA PRA Category 1)
Format: Online Streaming Video, MP3, MP4, Multiple Formats
Price: $1,295
Release Date: June 30, 2018
Expiration Date: June 30, 2021
Summary:

Stay Current with this Board Review in Hematology

The Brigham and Dana-Farber Board Review in Hematology CME program brings together adistinguished group of experts to present up-to-date diagnostic and therapeutic strategies. Enhance patient care and prepare for boards with topics like molecular genetics, leukemia, bone marrow failures, transfusion medicine and more. You will learn to:

  • Apply current/recommended hematology guidelines in clinical practice
  • Perform differential diagnosis of complex hematologic disorders
  • Identify and apply current therapeutic options for hematologic disorders
  • Evaluate and interpret up-to-date literature relevant to clinical practice in hematology
  • Illustrate knowledge of pathophysiology of hematology disorders
  • Apply knowledge gained to the ABIM certification/recertification
Credits: 44 (AMA PRA Category 1)
Format: Online Streaming Video, MP3, MP4, Multiple Formats
Price: $1,795.00
Release Date: June 30, 2018
Expiration Date: June 30, 2021
Summary:

Improve Patient Care in Hematology and Oncology

The Brigham and Dana-Farber Board Review in Hematology and Oncology will help improve clinical practice gaps in hematology and oncology derived from the American Board of Internal Medicine (ABIM) certification/recertification requirements. Relevant topics are addressed in case-based board review presentations. Improve patient care by learning to:

  • Perform differential diagnosis of complex hematologic and oncologic disorders
  • Identify and apply current therapeutic options for hematologic and oncologic disorders
  • Evaluate and interpret up-to-date literature relevant to hematology and oncology
  • Illustrate knowledge of pathophysiology of hematologic and oncologic disorders
  • Illustrate knowledge of pathophysiology as it applies to management of Hematology and Oncology disorders
  • Apply knowledge gained to the ABIM certification/recertification Hematology and Oncology examinations

Share This